Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Gilla Kaplan Sells 6,814 Shares

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Gilla Kaplan sold 6,814 shares of the company’s stock in a transaction on Monday, June 16th. The shares were sold at an average price of $10.38, for a total value of $70,729.32. Following the completion of the transaction, the director now directly owns 37,809 shares in the company, valued at approximately $392,457.42. This represents a 15.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Gilla Kaplan also recently made the following trade(s):

• On Friday, June 13th, Gilla Kaplan sold 15,000 shares of Tyra Biosciences stock. The stock was sold at an average price of $10.31, for a total value of $154,650.00.
• On Thursday, June 12th, Gilla Kaplan sold 30,000 shares of Tyra Biosciences stock. The shares were sold at an average price of $10.31, for a total transaction of $309,300.00.

Tyra Biosciences Stock Performance

Shares of NASDAQ TYRA opened at $9.59 on Wednesday. The stock has a market capitalization of $509.13 million, a P/E ratio of -5.88 and a beta of 1.07. The stock’s fifty day moving average is $9.67 and its 200 day moving average is $11.87. Tyra Biosciences, Inc. has a 52 week low of $6.42 and a 52 week high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. Equities research analysts forecast that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.

Institutional Trading of Tyra Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in TYRA. Rhumbline Advisers increased its stake in Tyra Biosciences by 4.1% in the fourth quarter. Rhumbline Advisers now owns 26,202 shares of the company’s stock valued at $364,000 after acquiring an additional 1,027 shares during the last quarter. BNP Paribas Financial Markets bought a new stake in Tyra Biosciences during the fourth quarter worth $60,000. RA Capital Management L.P. lifted its stake in Tyra Biosciences by 2.1% during the fourth quarter. RA Capital Management L.P. now owns 10,637,290 shares of the company’s stock worth $147,858,000 after purchasing an additional 220,681 shares during the last quarter. Two Sigma Advisers LP acquired a new stake in shares of Tyra Biosciences in the 4th quarter valued at $171,000. Finally, Deutsche Bank AG increased its stake in shares of Tyra Biosciences by 52.0% in the 4th quarter. Deutsche Bank AG now owns 18,909 shares of the company’s stock valued at $263,000 after purchasing an additional 6,466 shares during the last quarter. Institutional investors own 84.14% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on TYRA shares. Wedbush reiterated an “outperform” rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research note on Friday, March 28th. Piper Sandler began coverage on shares of Tyra Biosciences in a report on Wednesday, May 21st. They set an “overweight” rating and a $33.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Tyra Biosciences in a research report on Monday, March 31st. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $30.83.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.